Welcome to our dedicated page for Steris Plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris Plc stock.
Steris Plc (STE) is a global leader in medical sterilization and infection prevention solutions, serving healthcare, pharmaceutical, and life sciences industries. This news hub provides investors and professionals with timely updates on corporate developments shaping the critical field of healthcare safety.
Access consolidated Steris news including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our verified updates ensure you stay informed about developments impacting infection control technologies and medical equipment sterilization services.
Key content focuses on financial performance updates, FDA clearances for sterilization systems, contract service expansions, and R&D breakthroughs in decontamination science. All materials are sourced directly from company filings and authorized communications.
Bookmark this page for streamlined access to Steris' official announcements. Check regularly for updates on operational developments affecting healthcare providers and medical device manufacturers worldwide.
STERIS plc (NYSE: STE) reported strong financial results for Q1 fiscal 2025. Total revenue from continuing operations increased 8% to $1.3 billion, with constant currency organic revenue growing 6%. As reported EPS from continuing operations rose to $1.41, while adjusted EPS increased to $2.03.
Healthcare revenue grew 10% to $901.2 million, driven by 23% growth in consumables and 14% in services. Applied Sterilization Technologies revenue increased 7% to $249.8 million. Life Sciences revenue decreased 2% to $128.5 million due to a divestiture.
The company reiterated its fiscal 2025 outlook, expecting 6.5-7.5% revenue growth and adjusted EPS of $9.05-$9.25. STERIS remains confident in delivering on its full-year guidance.
STERIS plc (NYSE: STE) has announced a 5.6% increase in its quarterly dividend to $0.57 per share, marking the company's 19th consecutive year of dividend growth. The dividend will be payable on September 20, 2024, to shareholders of record as of September 5, 2024. This represents a $0.05 increase from the previous dividend.
STERIS, a global leader in infection prevention products and services for healthcare and life sciences, continues to demonstrate its commitment to shareholder value through consistent dividend growth. The company's focus on creating a healthier and safer world through innovative solutions underscores its strong market position and financial stability.
STERIS plc (NYSE: STE) has announced it will host a conference call on August 7, 2024, at 9:00 a.m. ET to discuss its fiscal 2025 first quarter financial results. The call can be accessed via www.steris-ir.com or by phone. A press release detailing the financial results will be issued after the U.S. market closes on August 6, 2024. For those unable to attend the live call, a replay will be available from 12:00 p.m. ET on August 7, 2024, accessible through the company website or by phone using the access code 5644736. This announcement provides investors and analysts an opportunity to gain insights into STERIS's recent financial performance and future outlook.
An affiliate of Peak Rock Capital has completed the acquisition of HuFriedyGroup, the dental segment of STERIS plc (NYSE: STE). HuFriedyGroup, founded in 1908, is a global leader in dental instruments, infection prevention products, and instrument management systems. The company serves customers in approximately 100 countries and employs around 1,500 people across more than 20 global facilities. Peak Rock Capital sees this acquisition as a significant investment opportunity, aiming to drive new product innovation and organic growth. The firm also plans to support complementary acquisitions to expand the product and brand portfolio.
STERIS plc (NYSE: STE) announced financial results for its fiscal 2024 fourth quarter and full year, with total revenue up 12% to $5.5 billion. U.S. GAAP earnings per diluted share were $3.81, adjusted earnings per diluted share increased to $8.83. The company reported a targeted restructuring plan. Fourth quarter revenue increased 10% to $1.5 billion. Healthcare segment outperformed, with revenue growth primarily in the United States. Fiscal 2025 outlook includes mid-to-high single digit revenue growth and double-digit earnings growth.
STERIS plc (NYSE: STE) declared a quarterly interim dividend of $0.52 per share, payable on June 26, 2024. The Company focuses on infection prevention in healthcare and offers healthcare, life sciences, and dental products globally.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
